subscribeSubscribe
CStone gets a win for sugemalimab in oesophageal cancer

CStone gets a win for sugemalimab in oesophageal cancer
Phil Taylor PHARMAPHORUM
03 Jan 2023
Share Share
EQRx receives MHRA marketing approval for sugemalimab

EQRx receives MHRA marketing approval for sugemalimab
John Pinching PHARMATIMES
21 Dec 2022
Share Share
For its two medicines, EQRx abandons its bold strategy to lower drug prices

For its two medicines, EQRx abandons its bold strategy to lower drug prices
STATNEWS
11 Nov 2022
Share Share
EQRx announces further results from phase 3 trial of sugemalimab

EQRx announces further results from phase 3 trial of sugemalimab
John Pinching PHARMATIMES
08 Aug 2022
Share Share
CStone presents updated results of a registrational study of sugemalimab

CStone presents updated results of a registrational study of sugemalimab
PRNEWSWIRE
07 Aug 2022
Share Share
Pfizer PD-L1 partner explores sale: Bloomberg

Pfizer PD-L1 partner explores sale: Bloomberg
Angus Liu FIERCEPHARMA
14 Jul 2022
Share Share
CStone and Pfizer announce NMPA approval of sugemalimab in NSCLC

CStone and Pfizer announce NMPA approval of sugemalimab in NSCLC
ASIAONE
06 Jun 2022
Share Share
CStone says GEMSTONE-302 study of sugemalimab met endpoint of overall survival

CStone says GEMSTONE-302 study of sugemalimab met endpoint of overall survival
PRNEWSWIRE
18 Jan 2022
Share Share
CStone completes enrollment in two key phase 3 trials of sugemalimab

CStone completes enrollment in two key phase 3 trials of sugemalimab
ASIAONE
18 Jan 2022
Share Share
CStone announces the clinical data from registrational study of Sugemalimab

CStone announces the clinical data from registrational study of Sugemalimab
ASIAONE
14 Jan 2022
Share Share